Education
About Us
Working with TipRanks
Follow Us
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (HK:6609)
:6609
6609 Stock Chart & Stats
HK$54.60
-HK$0.05(-0.24%)
At close: 4:00 PM EST
HK$54.60
-HK$0.05(-0.24%)
Day’s Range― - ―
52-Week RangeHK$24.30 - HK$71.25
Previous CloseN/A
Volume1.35K
Average Volume (3M)127.28K
Market Cap
HK$1.78B
Enterprise ValueHK$868.63M
Total Cash (Recent Filing)HK$718.20M
Total Debt (Recent Filing)HK$45.91M
Price to Earnings (P/E)38.2
Beta1.29
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.49
Shares Outstanding31,565,804
10 Day Avg. Volume119,990
30 Day Avg. Volume127,280
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)0.73
Price to Sales (P/S)2.80
P/FCF Ratio-92.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA sustained gross margin near 67.5% indicates strong product pricing, differentiated device/software offerings, and efficient production. Over 2–6 months this margin buffer supports reinvestment in R&D, absorbs SG&A, and underpins durable profitability as sales scale in cardiovascular devices.
Very Low Financial LeverageExtremely low debt-to-equity gives the company durable financial flexibility to fund capex, clinical trials, and strategic partnerships without heavy interest burden. This conservative capital structure reduces solvency risk and supports long-term investments and M&A optionality in healthcare markets.
Strong Free Cash Flow GrowthLarge improvement in free cash flow signals improving cash conversion and operational scalability. Over the medium term this strengthens the company’s ability to self-fund product development, commercial expansion, and post‑sales support programs key to durable growth in medical devices.
Bears Say
Negative EBIT MarginA negative EBIT margin implies operating costs (R&D, sales, or admin) outpace core operating earnings. If maintained, it threatens long-term operating profitability and requires either sustained margin improvement or continued external funding to support growth in the capital‑intensive medtech sector.
Weak Operating Cash ConversionOCF covering only 61% of net income suggests earnings include non‑cash items or working capital strains. Persistently weak cash conversion reduces internal funding for capex and commercialization, raising reliance on financing and constraining long‑term investment flexibility.
Modest Return On EquityA low ROE near 3.9% indicates limited efficiency in generating shareholder returns from equity. Over months this reflects slower monetization of assets or heavy reinvestment without commensurate profit improvement, which can limit investor returns if operational margins and cash conversion don't improve.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H News
6609 FAQ
What was Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price range in the past 12 months?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H lowest stock price was HK$24.30 and its highest was HK$71.25 in the past 12 months.
What is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s market cap?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s market cap is HK$1.78B.
When is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s upcoming earnings report date?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s upcoming earnings report date is Mar 26, 2026 which is in 31 days.
How were Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s earnings last quarter?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H released its earnings results on Aug 29, 2025. The company reported HK$1.493 earnings per share for the quarter, missing the consensus estimate of HK$10.316 by -HK$8.823.
Is Shanghai Heartcare Medical Technology Corp. Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price is currently Overvalued.
Does Shanghai Heartcare Medical Technology Corp. Ltd. Class H pay dividends?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H does not currently pay dividends.
What is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s EPS estimate?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Heartcare Medical Technology Corp. Ltd. Class H have?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H has 31,565,804 shares outstanding.
What happened to Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price movement after its last earnings report?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H reported an EPS of HK$1.493 in its last earnings report, missing expectations of HK$10.316. Following the earnings report the stock price went up 9.621%.
Which hedge fund is a major shareholder of Shanghai Heartcare Medical Technology Corp. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6609
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
179.09%
12-Months-Change
Fundamentals
Return on Equity
3.84%
Trailing 12-Months
Asset Growth
6.79%
Trailing 12-Months
Company Description
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
Shanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices worldwide. The company offers ischemic stroke thrombectomy, intracranial stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access devices. Its products are used for the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis, as well as for the treatment of hemorrhagic stroke. The company was formerly known as Shanghai Care Medical Technology Corporation Limited. Shanghai HeartCare Medical Technology Corporation Limited was incorporated in 2016 and is headquartered in Shanghai, the People's Republic of China.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) Earnings & Revenues
Technical Analysis
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
MicroPort CardioFlow Medtech Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Venus Medtech (Hangzhou), Inc. Class H
―